Medtronic plc (NYSE:MDT – Get Free Report) declared a quarterly dividend on Thursday, December 5th,RTT News reports. Stockholders of record on Friday, December 27th will be paid a dividend of 0.70 per share by the medical technology company on Friday, January 10th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.33%.
Medtronic has raised its dividend by an average of 6.5% per year over the last three years and has raised its dividend every year for the last 48 years. Medtronic has a payout ratio of 47.9% meaning its dividend is sufficiently covered by earnings. Analysts expect Medtronic to earn $5.86 per share next year, which means the company should continue to be able to cover its $2.80 annual dividend with an expected future payout ratio of 47.8%.
Medtronic Stock Performance
Shares of Medtronic stock traded down $1.18 on Thursday, reaching $84.14. The stock had a trading volume of 6,831,907 shares, compared to its average volume of 6,268,996. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.39 and a current ratio of 1.84. The business’s 50-day moving average price is $88.46 and its two-hundred day moving average price is $85.01. The stock has a market cap of $107.89 billion, a P/E ratio of 25.92, a price-to-earnings-growth ratio of 2.43 and a beta of 0.82. Medtronic has a fifty-two week low of $75.96 and a fifty-two week high of $92.68.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on MDT shares. Daiwa America upgraded Medtronic to a “strong-buy” rating in a report on Friday, August 23rd. Robert W. Baird cut their price target on Medtronic from $96.00 to $93.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Royal Bank of Canada upgraded Medtronic from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $98.00 to $105.00 in a report on Thursday, October 10th. Citigroup upped their price target on Medtronic from $85.00 to $92.00 and gave the stock a “neutral” rating in a report on Tuesday, October 1st. Finally, Wells Fargo & Company cut their price target on Medtronic from $106.00 to $98.00 and set an “overweight” rating for the company in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $95.27.
Check Out Our Latest Stock Analysis on Medtronic
Medtronic Company Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Featured Articles
- Five stocks we like better than Medtronic
- What to Know About Investing in Penny Stocks
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- How to Choose Top Rated Stocks
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.